Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Vir Biotechnology, Inc.VIR · Entity 4522 | EVP, General Counsel, Corp Sec | February 24, 2026 | February 26, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Vir Biotechnology, Inc.
Report date February 24, 2026 · Filed February 26, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 112,982 |
Ending reported balance
After 2026-02-25 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-02-24 · Sale · Disposed 3,117 · Balance 126,682 F1: Represents an automatic and mandatory sale of shares under a Rule 10b5-1 arrangement to satisfy the Issuer's tax withholding obligations in connection with the vesting of restricted stock units. The sale does not represent a discretionary trade by the Reporting Person. Row 2 · 2026-02-25 · Sale · Disposed 13,700 · Balance 112,982 F2: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 2, 2025. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents an automatic and mandatory sale of shares under a Rule 10b5-1 arrangement to satisfy the Issuer's tax withholding obligations in connection with the vesting of restricted stock units. The sale does not represent a discretionary trade by the Reporting Person.
F2: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 2, 2025.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 25, 2026 Filed Feb 26, 2026 21:54 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | SaleCommon Stock | 13,700 | $9.82 | $134,534.00 |
DisclosureSEC source: 0001628280-26-012393 · wk-form4_1772142894.xml · nonDerivative · entry 2 de Verneuil Vanina · CIK 0002036234 · EVP, General Counsel, Corp Sec 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 112,982 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 2, 2025. Read SEC document |
| February 24, 2026 Filed Feb 26, 2026 21:54 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | SaleCommon Stock | 3,117 | $9.53 | $29,713.11 |
DisclosureSEC source: 0001628280-26-012393 · wk-form4_1772142894.xml · nonDerivative · entry 1 de Verneuil Vanina · CIK 0002036234 · EVP, General Counsel, Corp Sec 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 126,682 F1 · kind: Represents an automatic and mandatory sale of shares under a Rule 10b5-1 arrangement to satisfy the Issuer's tax withholding obligations in connection with the vesting of restricted stock units. The sale does not represent a discretionary trade by the Reporting Person. Read SEC document |
| February 23, 2026 Filed Feb 25, 2026 00:10 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | SaleCommon Stock | 4,445 | $7.45 | $33,127.70 |
DisclosureSEC source: 0001628280-26-011328 · wk-form4_1771978240.xml · nonDerivative · entry 2 de Verneuil Vanina · CIK 0002036234 · EVP, General Counsel, Corp Sec 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 129,799 F3 · kind: Represents an automatic and mandatory sale of shares under a Rule 10b5-1 arrangement to satisfy the Issuer's tax withholding obligations in connection with the vesting of RSUs. The sale does not represent a discretionary trade by the Reporting Person. Read SEC document |
| February 22, 2026 Filed Feb 25, 2026 00:10 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | GrantStock Option (Right to Buy) · Derivative | 110,000 | $0.00 Strike: $7.56 | $0.00 |
DisclosureSEC source: 0001628280-26-011328 · wk-form4_1771978240.xml · derivative · entry 3 de Verneuil Vanina · CIK 0002036234 · EVP, General Counsel, Corp Sec 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 110,000 Underlying: Common Stock · 110,000 shares Expires 2036-02-21 F4 · derivative.exercise_date: 25% of the shares subject to the stock option will vest and become exercisable on February 22, 2027, and the remaining shares will vest in 36 equal monthly installments thereafter. Read SEC document |
| February 22, 2026 Filed Feb 25, 2026 00:10 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | GrantCommon Stock | 55,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-011328 · wk-form4_1771978240.xml · nonDerivative · entry 1 de Verneuil Vanina · CIK 0002036234 · EVP, General Counsel, Corp Sec 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 134,244 F1 · kind: Acquisition of restricted stock units (RSUs) pursuant to the Issuer's Equity Incentive Plan. F2 · balance_after: Includes 1,034 shares of common stock acquired by the Reporting Person on November 28, 2025 pursuant to an employee stock purchase program. Read SEC document |
| November 05, 2025 Filed Nov 7, 2025 20:27 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | SaleCommon Stock | 2,385 | $5.16 | $12,306.60 |
DisclosureSEC source: 0001628280-25-050592 · wk-form4_1762547269.xml · nonDerivative · entry 1 de Verneuil Vanina · CIK 0002036234 · EVP, General Counsel, Corp Sec 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 78,210 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 5, 2024. Read SEC document |
| November 03, 2025 Filed Nov 5, 2025 00:40 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | SaleCommon Stock | 1,365 | $5.86 | $8,003.00 |
DisclosureSEC source: 0001628280-25-049159 · wk-form4_1762303236.xml · nonDerivative · entry 1 de Verneuil Vanina · CIK 0002036234 · EVP and General Counsel 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 80,595 F1 · kind: Represents the automatic sale of shares to cover the Issuer's tax withholding and remittance obligation in connection with the vesting of restricted stock units. F2 · balance_after: Includes 2,500 shares of common stock acquired by the Reporting Person on May 30, 2025 pursuant to an employee stock purchase program. Read SEC document |
| February 26, 2025 Filed Feb 27, 2025 17:39 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | SaleCommon Stock | 7,373 | $9.14 | $67,402.49 |
DisclosureSEC source: 0001628280-25-008499 · wk-form4_1740677961.xml · nonDerivative · entry 1 de Verneuil Vanina · CIK 0002036234 · EVP and General Counsel 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 79,460 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 5, 2024. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.03 to $9.30, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| February 24, 2025 Filed Feb 25, 2025 20:34 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | SaleCommon Stock | 5,140 | $9.45 | $48,590.48 |
DisclosureSEC source: 0001628280-25-007690 · wk-form4_1740515688.xml · nonDerivative · entry 2 de Verneuil Vanina · CIK 0002036234 · EVP and General Counsel 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 86,833 F2 · kind: Represents the automatic sale of shares to cover the Issuer's tax withholding and remittance obligation in connection with the vesting of restricted stock units. Read SEC document |
| February 22, 2025 Filed Feb 25, 2025 20:34 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | GrantStock Option (Right to Buy) · Derivative | 70,000 | $0.00 Strike: $9.57 | $0.00 |
DisclosureSEC source: 0001628280-25-007690 · wk-form4_1740515688.xml · derivative · entry 3 de Verneuil Vanina · CIK 0002036234 · EVP and General Counsel 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 70,000 Underlying: Common Stock · 70,000 shares Expires 2035-02-21 F3 · derivative.exercise_date: 25% of the shares subject to the stock option vest and become exercisable on February 22, 2026, and the remaining shares vest in 36 equal monthly installments thereafter. Read SEC document |
| February 22, 2025 Filed Feb 25, 2025 20:34 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | GrantCommon Stock | 35,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-25-007690 · wk-form4_1740515688.xml · nonDerivative · entry 1 de Verneuil Vanina · CIK 0002036234 · EVP and General Counsel 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 91,973 F1 · kind: Acquisition of restricted stock units pursuant to the Issuer's Equity Incentive Plan. Read SEC document |
| December 02, 2024 Filed Dec 4, 2024 20:35 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | SaleCommon Stock | 76 | $8.22 | $624.73 |
DisclosureSEC source: 0001628280-24-049897 · wk-form4_1733344540.xml · nonDerivative · entry 1 de Verneuil Vanina · CIK 0002036234 · EVP and General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 56,973 F1 · kind: The shares were sold pursuant to a sale instruction entered into on May 28, 2024, whereby shares purchased on November 29, 2024 pursuant to the Issuer's employee stock purchase program were automatically sold six months after the instruction date. F2 · balance_after: Reflects ownership after acquisition by the reporting person on November 29, 2024 of 76 shares of common stock pursuant to the Issuer's employee stock purchase program, and sale of such shares on December 2, 2024. Read SEC document |
| November 06, 2024 Filed Nov 8, 2024 00:20 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | SaleCommon Stock | 4,397 | $10.11 | $44,453.67 |
DisclosureSEC source: 0001628280-24-046462 · wk-form4_1731025248.xml · nonDerivative · entry 1 de Verneuil Vanina · CIK 0002036234 · EVP and General Counsel 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 56,973 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 5, 2024. Read SEC document |
| November 05, 2024 Filed Nov 5, 2024 22:51 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | SaleCommon Stock | 2,347 | $9.47 | $22,225.15 |
DisclosureSEC source: 0001628280-24-045387 · wk-form4_1730847101.xml · nonDerivative · entry 2 de Verneuil Vanina · CIK 0002036234 · EVP and General Counsel 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 61,370 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 5, 2024. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.30 to $9.62, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| November 01, 2024 Filed Nov 5, 2024 22:51 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | SaleCommon Stock | 1,403 | $7.20 | $10,107.07 |
DisclosureSEC source: 0001628280-24-045387 · wk-form4_1730847101.xml · nonDerivative · entry 1 de Verneuil Vanina · CIK 0002036234 · EVP and General Counsel 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 63,717 F1 · kind: Represents the automatic sale of shares to cover the Issuer's tax withholding and remittance obligation in connection with the vesting of restricted stock units. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.